BMP pathway antagonism by Grem1 regulates epithelial cell fate in intestinal regeneration.

Bookmark this %label%

In homeostasis, intestinal cell fate is controlled by balanced gradients of morphogen signalling. The Bone Morphogenetic Protein (BMP) pathway has a physiological, pro-differentiation role, predominantly inferred through previous experimental pathway […]

» Read more

Intestinal Sulfation is Essential to Protect Against Colitis and Colonic Carcinogenesis.

Bookmark this %label%

Sulfation is a conjugation reaction essential for numerous biochemical and cellular functions in mammals. The 3′-phosphoadenosine 5′-phosphosulfate (PAPS) synthase 2 (PAPSS2) is the key enzyme to generate PAPS, which is […]

» Read more

Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome.

Bookmark this %label%

The microbiome directly affects the balance of pro-inflammatory and anti-inflammatory responses in the gut. As microbes thrive on dietary substrates, the question arises whether we can nourish an anti-inflammatory gut […]

» Read more

Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.

Bookmark this %label%

The effectiveness of µ-opioid receptor (MOPr) agonists for treatment of visceral pain is compromised by constipation, respiratory depression, sedation and addiction. We investigated whether a fentanyl analogue, (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP), […]

» Read more

DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.

Bookmark this %label%

Diet is thought to play a role in the development of inflammatory bowel disease (IBD), though the relationship between gluten intake and risk of IBD has not been explored. The […]

» Read more

Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study.

Bookmark this %label%

Bowel Ultrasonography (BUS) is a non-invasive tool for evaluating bowel activity in Crohn’s disease (CD) patients. Aim of our multicenter study was to assess whether BUS helps to monitor intestinal […]

» Read more

Infectious diseases affecting the small bowel – what not to miss.

Bookmark this %label%

This review summarizes infectious diseases involving the small bowel (SB) with a focus on recent literature related to diagnosis and pathophysiology.Typical symptom for SB infections is diarrhea, mostly self-limiting. Pathogens […]

» Read more

Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease.

Bookmark this %label%

Small bowel fibrosis is a significant burden on Crohn’s disease patients with limited effective medical treatments that then requires surgery. A better understanding of the molecular mechanisms causing fibrosis and […]

» Read more

Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.

Bookmark this %label%

Primary sclerosing cholangitis (PSC) is in 70% of cases associated with inflammatory bowel disease. The hypermorphic T108M variant of the orphan G protein-coupled receptor GPR35 increases risk for PSC and […]

» Read more

A Systematic Review of Monogenic Inflammatory Bowel Disease.

Bookmark this %label%

Advances in genomic technologies have led to increasing reports of monogenic inflammatory bowel disease (IBD). However, there has not been a detailed evaluation of the characteristics of the published cases […]

» Read more

Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases.

Bookmark this %label%

We conducted a retrospective cohort study to inform the safety of exposure to immunosuppressive and/or biologic agents around conception in expectant fathers with immune-mediated inflammatory diseases (IMIDs) on birth outcomes.Using […]

» Read more

Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know.

Bookmark this %label%

Despite advances in medical and surgical therapy in inflammatory bowel disease (IBD) management, intestinal stomas can be needed in a significant proportion of patients. The impact of stomas in patients’ […]

» Read more

Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis.

Bookmark this %label%

This review addresses the selection of biologic and small molecule therapy for patients with moderate to severe ulcerative colitis (UC). With several new treatment options approved within the past few […]

» Read more

Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Bookmark this %label%

Inflammatory bowel disease (IBD) is a lifelong condition with no cure. Patients with IBD might experience symptoms of common mental disorders such as anxiety and depression because of bidirectional communication […]

» Read more

Anal cancer and precancerous lesions: a call for improvement.

Bookmark this %label%

Anal squamous cell carcinoma is the most common type of anal cancer and is largely associated with anal human papillomavirus infection. The incidence of anal squamous cell carcinoma is increasing, […]

» Read more

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.

Bookmark this %label%

Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize efficacy and safety data of tofacitinib 5 or 10 mg twice daily […]

» Read more

Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.

Bookmark this %label%

This study compared pharmacokinetics, symptomatic and endoscopic efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab biosimilar CT-P13 (CT-P13 SC) versus intravenous CT-P13 (CT-P13 IV) in inflammatory bowel […]

» Read more

Therapeutic IL-6 trans-signalling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease.

Bookmark this %label%

A large unmet therapeutic need exists in inflammatory bowel diseases (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL-6/IL-6R blockade is limited […]

» Read more

Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease.

Bookmark this %label%

Clostridioides difficile infection (CDI) may complicate the course of ulcerative colitis and Crohn’s disease. The clinical presentation of CDI in this population is often atypical, and patients may experience exacerbations […]

» Read more

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial.

Bookmark this %label%

The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn’s disease (CD). Here we report final results […]

» Read more

Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance.

Bookmark this %label%

Tofacitinib is an oral, Janus kinase (JAK) molecule, which selectively inhibits Janus-associated tyrosine kinases JAK1 and JAK3. It has already shown efficacy in the treatment of rheumatoid arthritis and the […]

» Read more

Inflammatory bowel disease psychological support pilot reduces inflammatory bowel disease symptoms and improves psychological wellbeing.

Bookmark this %label%

This prospective service evaluation aimed to determine if integrated psychological support for patients with inflammatory bowel disease (IBD) enhanced outcomes. 75 patients were assessed and treated by a specialist liaison […]

» Read more

An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials.

Bookmark this %label%

Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. We aim to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for […]

» Read more

Identification of an Anti-Integrin αvβ6 Autoantibody in Patients with Ulcerative Colitis.

Bookmark this %label%

Ulcerative colitis is the most frequent type of inflammatory bowel disease and is characterized by colonic epithelial cell damage. Although involvement of autoimmunity has been suggested in ulcerative colitis, specific […]

» Read more

Gastrointestinal Infection and Risk of Microscopic Colitis: A Nationwide Case-Control Study in Sweden.

Bookmark this %label%

Gastrointestinal infections have been linked to changes in the composition and function of gut microbiome and development of inflammatory bowel diseases. We therefore sought to examine the relationship between gastroenteritis […]

» Read more
1 2 3 13